BR112012025392A2 - partícula viral liberada depois da infecção de células de mamíferos por citomegalovírus (hcmv) contendo uma proteína de fusão e seu uso - Google Patents
partícula viral liberada depois da infecção de células de mamíferos por citomegalovírus (hcmv) contendo uma proteína de fusão e seu usoInfo
- Publication number
- BR112012025392A2 BR112012025392A2 BR112012025392A BR112012025392A BR112012025392A2 BR 112012025392 A2 BR112012025392 A2 BR 112012025392A2 BR 112012025392 A BR112012025392 A BR 112012025392A BR 112012025392 A BR112012025392 A BR 112012025392A BR 112012025392 A2 BR112012025392 A2 BR 112012025392A2
- Authority
- BR
- Brazil
- Prior art keywords
- hcmv
- infection
- fusion protein
- mammalian cells
- cytomegalovirus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
partícula viral liberada depois da infecção de células de mamíferos por citomegalovírus (hcmv) contendo uma proteína de fusão e seu uso. a presente invenção refere-se a uma partícula viral liberada depois da infecção de células de mamífero mpor citomegalovírus de ser humano (hcmv), em que a) a particula está envolvida por uma membrana de lipídio que glicoproteínas virais estão embutidas, b) a partícula contém nem dna viral nem capsídeos; e c) a partícula contém uma proteína de fusão compreendendo uma ou mais partes do antígeno pp65 de célula t e pelo menos um peptídeo heterólogo, e em que pelo menos um peptídeo heterólogo é inserido na posição de aminoácido w175 ou a534 da consequência de aminoácidos de antígeno pp65 de célula t.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10003712 | 2010-04-06 | ||
| EP10003712.6 | 2010-04-06 | ||
| PCT/EP2011/001712 WO2011124371A1 (en) | 2010-04-06 | 2011-04-06 | Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012025392A2 true BR112012025392A2 (pt) | 2015-09-22 |
| BR112012025392B1 BR112012025392B1 (pt) | 2021-05-25 |
Family
ID=43923731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012025392-1A BR112012025392B1 (pt) | 2010-04-06 | 2011-04-06 | partícula viral liberada depois da infecção de células de mamíferos por citomegalovírus (hcmv) contendo uma proteína de fusão e seu uso |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9486517B2 (pt) |
| EP (1) | EP2556150B1 (pt) |
| JP (1) | JP5827312B2 (pt) |
| KR (2) | KR20170108167A (pt) |
| CN (1) | CN102933706B (pt) |
| AU (1) | AU2011238085B2 (pt) |
| BR (1) | BR112012025392B1 (pt) |
| CA (1) | CA2795346C (pt) |
| CY (1) | CY1118138T1 (pt) |
| DK (1) | DK2556150T3 (pt) |
| ES (1) | ES2601850T3 (pt) |
| HR (1) | HRP20161556T1 (pt) |
| HU (1) | HUE030704T2 (pt) |
| IL (1) | IL222229A (pt) |
| LT (1) | LT2556150T (pt) |
| MX (1) | MX2012011639A (pt) |
| MY (1) | MY162335A (pt) |
| PL (1) | PL2556150T3 (pt) |
| PT (1) | PT2556150T (pt) |
| RS (1) | RS55421B1 (pt) |
| RU (1) | RU2623172C2 (pt) |
| SG (2) | SG10201502271RA (pt) |
| SI (1) | SI2556150T1 (pt) |
| SM (1) | SMT201700002B (pt) |
| WO (1) | WO2011124371A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011101446A1 (de) * | 2011-05-10 | 2012-11-15 | Aicuris Gmbh & Co. Kg | Herstellung von "Dense Bodies" (DB) |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| AU2019280899A1 (en) | 2018-06-08 | 2020-10-08 | Vakzine Projekt Management Gmbh | Viral particle - based vaccine |
| EP3587566A1 (en) | 2018-06-29 | 2020-01-01 | Bodo Plachter | Hcmv vaccine strain |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733540A (en) * | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
| DE19910044A1 (de) | 1999-03-08 | 2000-09-14 | Bodo Plachter | Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff |
| US20080044384A1 (en) * | 2004-06-25 | 2008-02-21 | Medlmmune Vaccines, Inc. | Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens |
-
2011
- 2011-04-06 EP EP11713689.5A patent/EP2556150B1/en active Active
- 2011-04-06 SG SG10201502271RA patent/SG10201502271RA/en unknown
- 2011-04-06 HU HUE11713689A patent/HUE030704T2/en unknown
- 2011-04-06 KR KR1020177025664A patent/KR20170108167A/ko not_active Application Discontinuation
- 2011-04-06 PL PL11713689T patent/PL2556150T3/pl unknown
- 2011-04-06 CA CA2795346A patent/CA2795346C/en active Active
- 2011-04-06 WO PCT/EP2011/001712 patent/WO2011124371A1/en active Application Filing
- 2011-04-06 CN CN201180027797.9A patent/CN102933706B/zh active Active
- 2011-04-06 ES ES11713689.5T patent/ES2601850T3/es active Active
- 2011-04-06 DK DK11713689.5T patent/DK2556150T3/en active
- 2011-04-06 MX MX2012011639A patent/MX2012011639A/es active IP Right Grant
- 2011-04-06 KR KR1020127028033A patent/KR101839535B1/ko active IP Right Grant
- 2011-04-06 RU RU2012146775A patent/RU2623172C2/ru active
- 2011-04-06 US US13/639,636 patent/US9486517B2/en active Active
- 2011-04-06 AU AU2011238085A patent/AU2011238085B2/en active Active
- 2011-04-06 LT LTEP11713689.5T patent/LT2556150T/lt unknown
- 2011-04-06 RS RS20161007A patent/RS55421B1/sr unknown
- 2011-04-06 JP JP2013503035A patent/JP5827312B2/ja active Active
- 2011-04-06 PT PT117136895T patent/PT2556150T/pt unknown
- 2011-04-06 BR BR112012025392-1A patent/BR112012025392B1/pt active IP Right Grant
- 2011-04-06 MY MYPI2012004446A patent/MY162335A/en unknown
- 2011-04-06 SI SI201131016A patent/SI2556150T1/sl unknown
- 2011-04-06 SG SG2012071189A patent/SG184261A1/en unknown
-
2012
- 2012-09-27 IL IL222229A patent/IL222229A/en active IP Right Grant
-
2016
- 2016-10-25 CY CY20161101076T patent/CY1118138T1/el unknown
- 2016-11-22 HR HRP20161556TT patent/HRP20161556T1/hr unknown
-
2017
- 2017-01-02 SM SM201700002T patent/SMT201700002B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012025392A2 (pt) | partícula viral liberada depois da infecção de células de mamíferos por citomegalovírus (hcmv) contendo uma proteína de fusão e seu uso | |
| BR112015008930A2 (pt) | vacinas baseadas em partícula recombinante contra a infecção por citomegalovírus humano | |
| EA201492110A1 (ru) | Вакцины против впг-2 | |
| WO2011130617A3 (en) | An integrated bioreactor and separation system and methods of use thereof | |
| BR112014019901A8 (pt) | Proteínas de fator viii recombinante | |
| BR112015019066A2 (pt) | Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos | |
| EA201492202A1 (ru) | Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк | |
| BR112014023869A2 (pt) | proteínas nutritivas carregadas e métodos | |
| BR112015006763A2 (pt) | constructo de ácido nucleico, plasmídeo de vetor de transferência, vetor, células, partículas de vírus e composição ou conjunto de ingredientes ativos | |
| Chesnokova et al. | Epstein-Barr virus glycoprotein gB and gHgL can mediate fusion and entry in trans, and heat can act as a partial surrogate for gHgL and trigger a conformational change in gB | |
| BRPI1008083B8 (pt) | processo para a produção de uma linhagem de células amniócitos humanas permanentes, processo para a expressão transitória de polipeptídeos e proteínas recombinantes com o emprego da referida linhagem de células, e emprego da referida linhagem de células | |
| WO2012103496A3 (en) | Expression of soluble viral fusion glycoproteins in mammalian cells | |
| Serafini et al. | Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption | |
| EA201391666A1 (ru) | Рекомбинантная экспрессия растворимого интерферона | |
| BR112015020253A2 (pt) | formulações e métodos para produção aumentada de proteína recombinante | |
| BR112015027611A2 (pt) | Molécula de ácido nucleico isolada; célula hospedeira; vetor; proteína ou polipeptídeo isolado; imunorreagente específico de vírus da febre do vale do rift (rvfv); uso de uma composição; uso de uma composição para o diagnóstico de febre do vale do rift (rvf) em um indivíduo; e kit | |
| BR112014014917A2 (pt) | inibidores de fusão da membrana do hiv | |
| BR112015012776A2 (pt) | pino indicador para controle de conexões aderentes em componentes estruturais | |
| BR112022006595A2 (pt) | Origem viral de replicação para aumentar a produtividade de proteínas de células de mamíferos. | |
| Adler | Neutralizing activity of immunoglobulin preparations | |
| Hua et al. | Isolation and Culture of Bone Marrow Mesenchymal Stem Cells (MSCs) of Tibetan miniature pig, and Lentivirus-mediated EGFP Gene Transfer into MSCs | |
| UA72440U (ru) | ТЕСТ-СИСТЕМА ИММУНОФЕРМЕНТНАЯ ДЛЯ ВЫЯВЛЕНИЯ АНТИТЕЛ КЛАССА IgM К ВИРУСАМ ПРОСТОГО ГЕРПЕСА 1 И 2 ТИПОВ УНИФИЦИРОВАННАЯ "DIA-HSV 1/2-IgM-u" | |
| Samsell et al. | Transplacental Transmission Of Respiratory Syncytial Virus (RSV): Active Replicating Virus Is Isolated From Fetuses Of Late Pregnant Rats Infected With RSV At Midterm | |
| EA201992602A2 (ru) | Вакцины против впг-2 | |
| Marchant et al. | The Respiratory Syncytial Virus F And G Glycoproteins Bind Specific Cellular Receptors To Facilitate Virus Entry Into Bronchial Epithelial Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |